Molecular Markers for Patients with Thymic Malignancies: not Feasible at Present?

Avci, Nilufer; Cecener, Gulsah; Deligonul, Adem; Erturk, Elif; Tunca, Berrin; Egeli, Unal; Tezcan, Gulcin; Akyildiz, Elif Ulker; Bayram, Ahmet Sami; Gebitekin, Cengiz; Kurt, Ender; Evrensel, Turkkan

추천

검색

자료유형: 학술저널

저자정보: Avci, Nilufer (Department of Medical Oncology, Uludag University Faculty of Medicine) Cecener, Gulsah (Department of Medical Biology, University of Uludag, Institute of Health Sciences) Deligonul, Adem (Department of Medical Oncology, Uludag University Faculty of Medicine) Erturk, Elif (Department of Medical Biology, University of Uludag, Institute of Health Sciences) Tunca, Berrin (Department of Medical Biology, University of Uludag, Institute of Health Sciences) Egeli, Unal (Department of Medical Biology, University of Uludag, Institute of Health Sciences) Tezcan, Gulcin (Department of Medical Biology, University of Uludag, Institute of Health Sciences) Akyildiz, Elif Ulker (Department of Pathology, Uludag University Faculty of Medicine) Bayram, Ahmet Sami (Department of Thoracıc Surgery, Uludag University Faculty of Medicine) Gebitekin, Cengiz (Department of Thoracıc Surgery, Uludag University Faculty of Medicine) Kurt, Ender (Department of Medical Oncology, Uludag University Faculty of Medicine) Evrensel, Turkkan (Department of Medical Oncology, Uludag University Faculty of Medicine)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제15권 제8호

발행연도: 2014.1

수록면: 3,457 - 3,460 (4page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: Thymomas and thymic carcinomas are rare malignancies and devising clinically effective molecular targeted therapies is a major clinical challenge. The aim of the study was to analyze BLC2 and vascular endothelial growth factor receptor (VEGFR) expression and KRAS and EGFR mutational status and to correlate them with the clinical characteristics of patients with thymomas and thymic carcinomas. Materials and Methods: A total of 62 patients (mean age: $50.4{\pm}13.2$ years) with thymomas and thymic carcinomas were enrolled. The expression of BLC2 and VEGFR in tumor cells and normal tissues was evaluated by RT-PCR. The mutational status of the KRAS and EGFR genes was investigated by PCR with sequence specific primers. Results: The BLC2 and VEGFR expression levels did not differ significantly between tumor and normal tissues. Moreover, there were no clearly pathogenic mutations in KRAS or EGFR genes in any tumor. None of the molecular markers were significantly related to clinical outcomes. Conclusions: Changes in levels of expression of BLC2 and VEGFR do not appear to be involved in thymic tumorigenesis. Moreover, our data suggest that KRAS and EGFR mutations do not play a major role in the pathogenesis of thymomas and thymic carcinomas.

#Thymoma #Thymic carcinoma #BCL2 #VEGFR #KRAS #EGFR

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요